Huons said it has recently renewed its agreement with Biosyn Korea, the Korean offshoot of Biosyn Arzneimittel GmbH, a German pharmaceutical company, for the exclusive domestic distribution rights of Selenase, a selenium deficiency treatment.
This agreement is an extension of the existing exclusive domestic sales contract for Selenase signed by the two companies in 2013.
Under the renewed accord, Huon's will have exclusive domestic distribution rights for Selenase until 2028.
"We are pleased to have secured the continued exclusive distribution rights for Selenase in Korea," a Huons official said. "We will continue to expand the supply of Selenase and contribute to the improvement of public health."
Selenase is a medication for the treatment of selenium deficiency. It was first launched in 1987 by Biosyn and is currently a blockbuster item with annual sales of 12 billion won ($9 million) as of 2022.
Related articles
- Huons expands free support for CGM device to ease financial strain on diabetic patients
- Huons reports Q2 net income of ₩14.9 billion, up 98.2% year-on-year
- US FDA OKs Huons’ 2% lidocaine for local anesthesia
- Huons, Kakao Healthcare to co-market Dexcom's continuous glucose monitoring device
- Huons Global’s Q3 operating profit jumps 75% on strong international sales